Showing posts with label access to drugs. Show all posts
Showing posts with label access to drugs. Show all posts

Tuesday, 28 October 2014

Afro Leo

Ebola & IP, Adwords decision

It did not take long for an article to appear seeking to blame intellectual property for perpetuating the Ebola crisis affecting West Africa, and here it is: "Ebola Vaccine Delay May Be Due To An Intellectual Property Dispute":

"For the past six weeks, about 800 to 1,000 doses of an experimental ebola vaccine have been sitting in a Canadian laboratory instead of being dispensed to West Africa. The delay, it would now appear, may be on account of an intellectual property spat."

The article has attracted no less than 3000 FB likes, 73 comments and 15 top of class stars! But what unfortunate rubbish it is.

The piece stirs and seeks to capitalise (rather successfully it would seem) on two emotive issues (IP & the lack of access to drugs & the ebola outbreak) without a proper analysis of whether in fact there is a relationship between the two. It simply alludes to a connection and lets the groundswell begin on what the author suggests is "epidemic profiteering [caused by the patent system]" but with no real support for his view.

Fortunately not all commentators have agreed with him. In fact Catherine Saez of the excellent IP-Watch has penned several more balanced articles. Some of these were published well before Dvorsky's opportunistic outcry, which rather strangely does not mention them. Unfortunately, Catherine's articles do not appear to have reached as many as Dvorsky's piece has, attracting just a handful of comments but such is life on an IP blog. Hopefully, this post gives them just a little more air.

And, to a completely different IP issue, news just in is that those who have been following the Adwords dispute in RSA can expect to receive a judgement summary tomorrow.


Read More

Friday, 9 March 2012

Darren Olivier

Kenya waits on landmark decision affecting access to drugs due out today

Protestors outside court: Suleiman Mbatiah/IPS
The Constitutional Division of the High Court is expected to deliver a landmark judgment on certain suspended clauses in the Anti-Counterfeit Act of 2008 according to Africa Science News. The case is as controversial as it is important not only for Kenya but for the entire East Africa region considering new anti-counterfeit legislation. The nub of the complaint is that the current clauses prevent access to affordable generic medicine and are overly protective to rights holders.

John Syekei previously wrote this piece for Afro-IP summarising the issues and commenting that his concern is that the Court will favour public interest groups without a full analysis the law, as drafted. Essentially he believes the problem is bad drafting.

"The question that begs is whether the Constitutional Court shall in its interpretation of the [Anti-Counterfeit] law, redraft the AC law , re-look at the existing Patent laws in Kenya and issue a judicial comment on them or shall it send it back to Parliament? This decision will definitely redefine the landscape as we know it as relates to Patent protection of branded medicines, Trademark rights and Counterfeit practices." ...

An update from anyone in the region after the decision would be appreciated.

Read More

Monday, 7 March 2011

Darren Olivier

Canada's One License Solution Update

snail's pace
Progress on the debate around Canada's innovative "one licence solution" (see earlier post on Afro-IP here) for creating access to life saving drugs is contained in a piece in the Ottawa Citizen (click here):

"Advocates say the private member’s bill [up for a vote on Wednesday] contains reforms needed to make Canada’s Access to Medicines Regime (CAMR), adopted unanimously by Parliament in 2004, actually function. But opponents insist it won’t work, largely because Canadian generic drugs are too expensive to attract interest from impoverished developing nations."

Whilst the article contains interesting dialogue on the debate and as noble as the legislation appears to be, the people without access to these drugs have been dying since that debate started almost a decade ago. It is a depressing state of affairs because, assuming that the legislation has the potential to work, the real challenge will only commence once the legislation is in place and if the time taken to debate the legislation is any indication of the time it will take to overcome this future challenge, one feels that the legislation is bound to fail anyway.

Coming up this week: the latest Gap Case in RSA, an IP update from Kenya and Afro-IP gets more contributors. Stay tuned.


Read More

Wednesday, 22 September 2010

Darren Olivier

Fake drug progess in Kenya! and compulsory licensing

Kenya's Daily Nation reports that efforts to curb counterfeit drugs in the region are bearing fruit alongside some disturbing news about how Kenyans are being diagnosed with incorrect drugs:

"The minister [Medical Services minister Anyang’ Nyong’o], however, said counterfeit drugs were no longer a big problem in the country because of a cross-border effort to reduce their prevalence."


“Working closely with the police, CID and Interpol in these countries, we have been able to reduce significantly the prevalence of fake drugs,” says Chief Government Pharmacist Kipkerich Koskei.


Afro Leo wonders whether just the one significant push against counterfeit drugs (see Afro-IP post here) has made that much impact or whether there is indeed a glimmer of light. Perhaps readers will comment below.


Meanwhile Alec van Gelder has written in to Afro Leo defending his article in the WSJ reported here and informing us of a paper that will be published soon explaining in more detail his position.


Alec has also directed us to this article published just recently: Epstein, Richard A. and Kieff, F. Scott, Questioning the Frequency and Wisdom of Compulsory Licensing for Pharmaceutical Patents (August 17, 2010). U of Chicago Law & Economics, Olin Working Paper No. 527. Available at SSRN: http://ssrn.com/abstract=1660702 :


"Any need to help poor people gain access should not rely on CL, but instead should rely on tools precisely aimed at that purpose, including direct government purchases of patented drugs from their manufacturers at negotiated prices."

Thanks Alec.
Read More

Friday, 10 September 2010

Afro Ng'ombe

African Highlights from Access to Knowledge A Guide for Everyone

The 1709 Blog has a post giving an overview of the 2nd Edition of Access to Knowledge A Guide for Everyone (large pdf file), but Afro-Leo wanted to make special mention here of a number of portions of the book specifically highlighting Africa.

Anti-Counterfeiting in East Africa

The book discusses the EAC Anti-Counterfeits Bill, Uganda’s Counterfeit Goods Bill and Kenya’s Anti-Counterfeit Act of 2008 in terms of the Millennium Development Goals,

“East African countries were facing the risk not attaining the millennium development goal (MDG) on universal treatment of people living withHIV and AIDS, malaria and other diseases if the region’s parliaments adopted the anti-counterfeits policy and bill under consideration in the region, the IPS report also noted.”

Afro-Leo recommends reading the excellent coverage by fellow Lions on Kenya’s Anti-Counterfeit Bill with follow-up.

Internet Access

Intellectual property laws are not the only barrier to accessing knowledge.  When resources are legally available but physically unattainable, they knowledge remains as inaccessible.  In relation to this, the book discusses the recent improvements in internet access across the continent (p. 110).  But, as the book points out, internet without opportunities to access it or an understanding of how to use it is useless.  The Kenya Education Network Trust is given as an example of good institutional support for use of the internet, and promoting information and communication technologies. [Another source, Technology Times reports that Nigeria is also working nationally on this issue, potentially appointing a Minister of ICT.

In addition to national programs like the one in Kenya, many people in African countries also have the opportunity to learn about and use the internet through the large number of non-governmental organizations operating across the continent.  As connection points and knowledge about how to utilize the internet increase, the cost of computers are decreasing, resulting in more opportunities for people to actually use the internet on a regular basis.

New Types of Patents

The book address three types of patents with distinct ramifications for Africa and other parts of the developing world: pharmaceutical patents (p. 51), agricultural patents (p. 53), and biopiracy-based patents (p. 55).  Most people following intellectual property issues in Africa are familiar with the debates around pharmaceutical patents: Preventable diseases go untreated because patented medicines are expensive, but if drug developers aren’t rewarded with patent rights, will they make the huge investments required to discover new breakthroughs.  The book discusses the history of patents and phrama and puts for some alternative systems.

“One view on the abuse of pharmaceutical patents is that perhaps patents were the wrong mechanism for funding pharmaceutical production all along.”

Agricultural patents, like pharmaceutical patents, deal with an important component of daily survival, food security.  As new types of seeds are patented, seeds that produce sterile plants, farmers are faced with the possibility of having to pay large amounts of money for seeds they used to just keep from the previous year’s harvest.  Although most African farmers still save their seeds and replant, these countries may move closer to the industrialized country model of planting sterile-plant seeds as companies develop seeds specifically for the various unique growing conditions across Africa.

Biopiracy-based patents are patents generally obtained by companies in industrialized countries who have ‘discovered’ some new compound or plant that a local community has been using for a very long time.  This is an area that overlaps greatly with Traditional Knowledge and Genetic Resources.  While the book acknowledges this as a problem - “The failure to address issues related to traditional knowledge and bioresources even whilst ratcheting upward the protection granted to new inventions doubly jeopardises developing countries.” – this is one place where there’s no potential solutions offered.

Broader Level Points

Other areas of the text that may be of interest with respect to Africa (page numbers or of the pdf, not the printed numbers on the page):

  • Background discussion of the Doha Declaration and Development Agenda, p.23.
  • Libraries as players in Access to Knowledge, with mention of Bibliotheca Alexandria in Egypt, p. 28
  • Academia as a player in Access to Knowledge, with mention of the Wits University LINK Centre in South Africa, p. 29
  • Section 2.1.1 Copyright law and developing countries, p. 41
  • The United State’s Special 301 Report’s effect on developing countries, p. 63
  • Open Access activities in developing countries, p. 78
  • Electronic libraries in developing countries, p. 76
Read More

Thursday, 9 September 2010

Darren Olivier

WSJ article under fire - access to drugs - what's the problem?

Afro-IP recently highlighted an opinion by Alec Van Gelder in the Wall Street Journal (see here) that has attracted the attention of the excellent SpicyIP blog in this piece here, entitled "WSJ mixing up issues in Access to Drugs debate", and by Doctors Without Borders here.

Whilst admitting that the opinion raises a number of valid points the Spicy IP author, Berkeley School of Law student Swaraj Paul Barooah, feels that the WSJ gets it wrong in a number of respects. He feels that lack of compulsory licensing is due to political pressure and raises an issue that access to drugs is hampered by a fact that, for example, some drugs do not exist at all. In short he appears to feel that the WSJ article is too simplistic in its approach to the "multi-faceted" problem. Michelle Childs, writing on behalf of DWB, feels that the debate has moved on highlighting DWB's efforts to provide innovative access. She feels that "[the opinion] posits a false choice between keeping the price of medicines affordable and ensuring that the medicines actually reach patients in the developing world".

The opinion is available on subscription only and Afro Leo is hoping Alec will respond for the benefit of our readers.

Read More

Monday, 30 August 2010

Darren Olivier

WSJ reports on the Access to Drugs debate

It is always good to see an article on Africa in the Wall Street Journal. Alec van Gelder, who has commented on this blog before writes that:

"The drug companies do make easy targets but that doesn't make them villains. The life-saving treatments they create remain Africa's best hope. The misguided battle against pharmaceutical companies' patent rights will only make Africa's health crisis worse..."

Right - seized drugs (AFP)

The full article explains that lack of domestic infrastructure and misguided aid are the real villains (I was able to read article first time without the need to subscribe and hope you can too).

Afro Leo was in a conversation this month with a fork lift driver and building site manager from Durban who explained that every person on his 30 strong team was infected. "You would not notice the difference until they do not take their ARVs. Men capable of lifting bags of cement for an entire shift, die within months." I asked him why they would not take their ARVs and he explained that it was sometimes cost and sometimes supply. For further reading on the "patents v access" debate on this blog, type in "access to drugs" in the search block on Afro-IP.

Meanwhile late last week, Interpol, East Africa announced the seizure of 10 tonnes of counterfeit drugs. Yahoo news article here. The WHO, one of the targets of Alec's article, ironically gets part of the credit. The massive raid nicknamed Mamba III involved targets in Burundi, Kenya, Rwanda, Tanzania and Uganda. Given the recent debate over Kenya's definition of "counterfeit" (which included comment on the WHO's definition of the term) Afro Leo welcomes clarification on whether the confiscated drugs were fakes or actually generics that may fall within the definition of "counterfeit".

General


* Congratulations to Nevashni Pillay who got Friday's "Where in Africa?" correct! This Friday Afro Leo will continue his travels to IP hubs across Africa.


* Last week we reported on the Africa Media Rights Watch initiative here. Dugie Standeford, writing for the excellent IP Watch, provides further information on the initiative in this piece here
Read More

Thursday, 22 July 2010

Darren Olivier

WHO - a response

The efficient John Syekei, has punched out an update on the anti-counterfeiting decision in Kenya for us, and a response to the post immediately below. According to the update, John explains that the WHO template legislation is flawed and states that the Constitutional Court decision over the anti-counterfeiting clause will be a landmark decision.

"The question that begs is whether the Constitutional Court shall in its interpretation of the [Anti-Counterfeit] law, redraft the AC law , re-look at the existing Patent laws in Kenya and issue a judicial comment on them or shall it send it back to Parliament? This decision will definitely redefine the landscape as we know it as relates to Patent protection of branded medicines, Trademark rights and Counterfeit practices." ...

Full text:

"I believe, WHO has admitted its template legislation is flawed.

As an update on the Kenya case ( Kenya being one of the few African countries that has effected a law to legislate against counterfeits) :

Kenya’s Constitutional Court is due to set a date today for a hearing on the inter partes substantive application against the Anti-Counterfeit Act of 2008, of which clauses pertaining to medicines have been suspended pending the court’s decision on whether the law violates the right to health and life. As I had reported earlier, in April 2010, Justice Roselyn Wendoh appreciated that the petitioners would suffer irreparable damage if their plight were not addressed. In her ruling, Justice Wendoh issued a conservatory order on the application of the law to medicines until a verdict is delivered in the case.

Parties enjoined in the case were supposed to file written submissions for the main constitutional application before Jul 22.

Today, the Constitutional Court will confirm that all parties including the Interested parties , have filed their written submissions and then set a date when it will hear each party highlight in brief a summary of their written submissions and their prayers. The Court will ask questions on that day as well.

In my view, this is public interest litigation that touches on the fundamental right to life and the commercial right of patent brand owners and generic pharma brand owners to have fair treatment in Kenya. What stand will the Court take. It is clear , as has been suggested by WHO, that poor legislative drafting has led to this problem. The question that begs is whether the Constitutional Court shall in its interpretation of the law, redraft the AC law , re-look at the existing Patent laws in Kenya and issue a judicial comment on them or shall it send it back to Parliament? This decision will definitely redefine the landscape as we know it as relates to Patent protection of branded medicines, Trademark rights and Counterfeit practices.

My feeling is that, with proper education at the enforcement level- the Inspectors appointed under the debatable AC act who include Customs officers, these problem would not be the mountain it seems to be. The devil is in the details. It is important to Kenyans that they have accessible drugs especially for HIV carriers , looking at the dynamics of poverty in Kenya and the fact that many of those HIV carriers form a large portion of the people who earn less than 1 US Dollar a day.

It is argued that the law contravenes sections of the Industrial Property Act of 2001, including section 58 (2) providing for parallel importation and section 80 on government use. Section 58 (2) waives patent rights pertaining to some products on the market in Kenya or in any other country or imported into Kenya and essentially facilitates, accessibility to affordable medicines by all," With the Industrial Property Act of 2001, Kenya used the flexibilities afforded to least developed countries in the Doha Declaration of 2001 with regards the Trade-Related Aspects of Intellectual Property (TRIPs) agreement.

Health rights activists argue that developed countries ( read big pharmaceutical companies who form a majority of the patent owners) are trying to force TRIPs-plus agendas (intellectual property rights protection that goes beyond TRIPs) regarding medicines on developing countries in favour of IP rights holders.

Activists argue that the Anti-Counterfeit Act of 2008 fails to acknowledge and to specifically exempt generic medicines from the definition of counterfeits. Moreover, TRIPs identifies intellectual property (IP) rights as "territorial rights". IP on medicines would only be protected in the territory where it is registered. However, the Anti-Counterfeit Act of 2008 upholds IP rights registered in countries outside Kenya.

I believe, having looked at the trends the Constitutional Court has been taking lately, that the decision will most likely be in favour of the public interest groups rather than a proper analysis of the law as drafted."
Read More

Wednesday, 21 July 2010

Darren Olivier

The WHO - an admission?

The World Health Organisation (WHO) agrees that the anti-counterfeit legislation that has been adopted or that is under consideration in East Africa threatens the accessibility of affordable generic medicines according to this report published by IPS Inter Press Sevice. The report follows the recent Kenyan case kindly reported by John Syekei here. Afro-IP generated some helpful comments from co-blogger Paul Asiimwe and others here, one of which was that the Kenyan definition of "counterfeiting" was almost identical to the WHO definition (WHO site -here). Afro Leo has not had the opportunity to compare the texts and would welcome views. Does the WHO admit that its template legislation is flawed?
Read More

Saturday, 22 May 2010

Darren Olivier

Origins of Kenya's controversial legislation

"The international push behind Kenya's controversial Anti-Counterfeit Act of 2008 dates back as far as October 2006 when the World Customs Organisation held its first intellectual property rights (IPRs) seminar in Kampala, the capital of neighbouring Uganda, focusing on East African governments' enforcement of these rights." This AllAfrica report (Wambi Michael and Christi van der Westhuizen) gives some detail about the origin of the legislation that was recently suspended in Kenya. Was the agenda about enforcement of IPRS by global multinationals or about improving access to quality medicines?


For further background searching "access to drugs, Kenya" in the search box alongside.
Read More

Sunday, 25 April 2010

Darren Olivier

South Africa's new Director General of Health

Malebona Precious Matsoso, a Director in Public Health Innovation and Intellectual Property (PHI) for the World Health Organisation, has returned to South Africa to be appointed the new Director-General of Health. This puts her in charge of RSA's health issues reporting to and advising the Health Ministry. It's a big job. Her stance as far IP and drugs is concerned is hinted at in a paper she delivered at the International Conference for Drug Regulation Authorities:

"In conclusion, there are several interventions that could further improve the selection and quality of drugs. First, for the selection of drugs, the essential drugs list should be regularly updated, and provincial therapeutics committees should be established or strengthened. Updated and locally relevant information on efficacy and safety of antiretroviral drugs should be disseminated. For the quality of drugs, results of quality control tests should be used as the basis of prequalification of suppliers in adjudicating tenders. Law enforcement, particularly within the developing country context, should be strengthened in order to combat counterfeit drugs."
Read More

Tuesday, 13 April 2010

Darren Olivier

LESI, fake drugs and african ambience

Last evening Afro-Leo had the opportunity to join the LESI conference which is being run on his doorstep, in downtown Sandton (see You Tube clip below). It has a super programme which can be downloaded here. This morning's slot is dedicated to publicly funded research with a comparative approach across the USA, Japan, Australia and its green shoots (and not uncontroversial) development in South Africa, which should be great fun.
Last evening's festivities took us to Moyo, an upmarket African experience, near Zoo lake. Afro Leo was invited to join a table of 4 Russian and 2 Estonian IP attorneys from different firms, who had taken time out from networking to enjoy the five course African fare, face painting, drum rolls and the somewhat curious injection of Italian background music. If the Italian music was a bit of a surprise, the conversation (which was politely, English) covered topics such as where to ski in Europe, Muslim traditions, why Russia has a public holiday for all New Year celebrations and Russia's own problem with fake drugs - the IP attorney next to me travels to Germany for her family's medicines!
Overall, a delightful reminder why it is good to be part of an IP community and why Africa can (and should) host more international IP events. Credit to LESI, Johan Du Preez and his team for organising the event.

Read More

Wednesday, 7 April 2010

Darren Olivier

Analysing alternative methods to fighting fake drugs

Julian Harris at International Policy Network responds to some points in the Now Lebanon article (see previous past here and commentary (thank you Paul and Graham) here) which postulates various alternative methods for fighting fake drugs:

"Firstly, implementing a state-run healthcare system is not a way of reducing levels of counterfeit medicines. The Member of Parliament’s rather bizarre comparison between France and ‘Africa’ would be amusing if it wasn’t so dangerously misleading. One could just as easily look at the situation in the USA, where there is no universal healthcare system (as yet) and extremely low levels of counterfeit medicines.

Environments with high levels of fake drugs are characterised by weak trademark protection, slow or politically-influenced courts, and high corruption. Associating the problem with tangential issues such as a lack of ‘social’ healthcare should not be done without considerable supporting evidence.


Of the solutions presented in the article, the most promising is the (voluntary) adoption by private companies of new technologies. These technologies can preserve the identity of their products, guaranteeing to patients that they’re purchasing the real thing. The growth of such technologies is to be welcomed, especially in areas where protecting IP is extremely difficult.


Holograms, however, are not a particularly advanced technology and have already been faked for use on counterfeit medicines.


Sadly an increase in levels of inspectors is not necessarily a solution. In India, to take one example, there are cases of inspectors taking bribes and even conspiring in the provision of fake drugs to public hospitals. A recently-exposed drug racket in Chennai has partially been blamed on drug inspectors exploiting their positions. In many countries, increasing regulation of this kind simply increases the scope for corruption and illicit counterfeits dealing.

Citations:

Piyush Diwan, 14th December 2008,
"Presence of flourishing fake medicine racket in Orissa confirmed by Vigilance reports”,

“
Why watchdogs failed to bark”, 27th March 2010"

It seems as if we are back to effective IP (and its enforcement) as a crucial part of the solution. All the more reason to get that Kenyan definition to work but is that what the Kenyan constitutional case is all about? Court papers and/or further comment would be welcome.
For more posts on this complex, intriquing and important debate click here.
Read More

Tuesday, 6 April 2010

Darren Olivier

Kenyan anti-counterfeit legislation debate

My earlier post concerning the Anti-Counterfeiting Act challenge in Kenya here, has lead a number of useful responses. The first is copied below as the writer wishes to be anonymous:

"The Kenya Anti-Counterfeiting Act says “counterfeiting means taking the following actions without the authority of the owner of intellectual property right subsisting in Kenya or elsewhere in respect of protected goods – (d) in relation to medicine, the deliberate and fraudulent mislabelling of medicine with respect to identity or source, whether or not such products have correct ingredients, wrong ingredients, have sufficient active ingredients or have fake packaging” (my emphasis). Do you interpret this definition of counterfeit medicine as including legitimate generics? [Darren Olivier - no I do not] Again, the definition in the Act is almost identical to the official WHO definition counterfeit medicines.
From my basic understanding of the Act, I believe that the definition is fine, and that the real potential problem is that the Kenyan Revenue Authority (and other inspectors under this Act)will need training and established procedures to be able to quickly and efficiently tell the difference between legitimate drugs (both branded and generic) and counterfeits. Delay in releasing legitimate generic or branded drugs may occur if the KRA is unable to quickly identify legitimates from counterfeits. From what I’ve heard, the Kenyan Government is aware of this need for training and procedures. It seems that the activists – rather than trying to obfuscate the issue by claiming that the Act is “vague” – should be calling for the Govt of Kenya to put in place adequate resources and systems to ensure that their inspectors are able to implement the Act properly."
Further comment would be appreciated. Paul, David?
Read More

Wednesday, 31 March 2010

Darren Olivier

Some alternative methods to fighting fake drugs

The problem of fake drugs is not new to this blog and nor is the debate over whether IP legislation and reliable enforcement effectively deals with the problem. Earlier this month, Afro-IP understands that the Kenyan Anti-Counterfeit legislation was brought to task before the Constitutional Court. Why - amongst other things, because activists (not only those with self interest in the production of generic drugs) believe that stopping the supply of generics (because they fall within the definition of "counterfeit" in the Act) poses serious health risks to developing nations. As one article puts it - a seizure disrupts tenuous supply chains increasing the risks of stock-outs in health facilities. However, IP (on its own and for its own sake) should never be touted as the only solution to this very complex situation, crucial as it may be. An article in Now Lebanon, also illustrating that fakes drugs is not just an African problem, reveals some of these other solutions including the notion that a state run health system significantly reduces the problem of counterfeit drugs:

“In a social health care system that covers all citizens, [the prevalence of] counterfeit medicine deceases, while the opposite is true [with privatized systems],” he said. “In France for example, [an estimated] zero percent of medicine is counterfeit, whereas in Africa the percentage can reach up to 30 percent.”

"Health Minister Mohammad Khalifeh says that his ministry currently sends out inspectors to over 80 pharmacies on a daily basis to buy samples that are then tested. The customs department is also collaborating by increasing surveillance on the country’s borders to control smuggling. Meanwhile, new electronic methods are being used, with drug companies asked to tag their packages with certified barcodes and serial numbers to guarantee authenticity."

“We are bringing it to the public’s attention, not only to highlight the apprehension of criminals but also for awareness purposes. The public should know which pharmacist to trust and how to buy their drugs through legal channels and not to resort to online buying and home deliveries, which is at the root of this problem.”

"To guarantee the product, the syndicate offers its members a hologram to place on medicine packets as a sign of commitment to the specifications of the Ministry of Health and a responsibility toward the proper channeling of drugs from producers to consumers. Syndicate members, according to Phares, have a written and moral obligation to these commitments and represent 90 percent of local suppliers."
Read More

Tuesday, 26 January 2010

Darren Olivier

WHO's strategy good news for Africa but what about IP?

"The World Health Organization (WHO) is considering a plan to ask governments to impose a global consumer tax on such things as Internet activity or everyday financial transactions like paying bills online. Such a scheme could raise "tens of billions of dollars" on behalf of the United Nations' public health arm from a broad base of consumers, which would then be used to transfer drug-making research, development and manufacturing capabilities, among other things, to the developing world (sounds like good news for Africa). The multibillion-dollar "indirect consumer tax" is only one of a "suite of proposals" for financing the rapid transformation of the global medical industry that will go before WHO's 34-member supervisory Executive Board at its biannual meeting in Geneva." (Foxnews

"In May 2003 [WHO] established an independent, time-limited body, the Commission on Public Health, Innovation and Intellectual Property Rights, to collect data and proposals from the people and institutions involved and present an analysis of intellectual property rights, innovation and public health, including appropriate funding and incentive mechanisms for the creation of new medicines and other products against diseases that disproportionately affect developing countries. The Commission concluded that intellectual property rights provide important incentives for the development of new medicines and medical technologies. Those rights are not, however, an effective incentive when patients are either too few or poor. As a result, there is a gap in the innovation cycle: in some cases no product exists to address the health needs of the poor, and, in other cases, products exist, but little effort is made to ensure that they are affordable for poor communities. Other incentives, financial mechanisms and coordination among stakeholders are needed."

Published a few days ago is the full Report of the Expert Working Group set up by WHO as a consequence of the Commission's conclusions to develop proposals for new and innovative sources of financing, to stimulate research and development. Some of the controversy over its publication (including an apparent neglect over IP rights) is revealed by Foxnews here.

Read More

Thursday, 21 January 2010

Darren Olivier

When bad milk looks like sour grapes

Afro-IP encourages comment but two articles "in answer" to its post "Is Uganda's proposed anti- counterfeit goods legislation bad milk?" were really quite unexpected.

Alec van Gelder of the International Policy Network kindly wrote in:

"Here’s a response from International Policy Network, a think-tank based in London, to the rather alarmist interview with Sisule Misungu [Musungu] that we think rather misses the point: http://bit.ly/7JhxpK. The usual activist argument against IPRs ignores the glaring reality that the poor in poor countries would benefit for better protection of all property rights – tangible and otherwise – and that in some case this really is a life or death issue."

The Daily Nation, on the other hand, really went to town. Their article "Kenya May Buy Ugandan ARV's" by Business Daily surely goes some way to exonerating Uganda's president as a naive politician and makes a case for comprehensive IP legislation to protect home grown IP rights.

Musunga, should you be ashamed.
Read More

Wednesday, 20 January 2010

Darren Olivier

Is Uganda's proposed anti-counterfeit legislation bad milk?

Afro Leo has come across an interesting Q&A session with Sisule Musungu president of Geneva-based IQsensato, a non-profit research and communications organisation providing a platform for developing world researchers to influence international policy-making on development. In short Sisule argues that 'Intellectual property rights constitute one of the last comparative trade advantages that industrialised countries enjoy.' and that the adoption of these laws by for example, Uganda, perpetuates the need for industrialised countries to preserve their global trade position [as opposed to genuinely assisting developing countries.] He believes that the President of Uganda has been hoodwinked into believing that anti-counterfeit legislation will solve the problem of children drinking bad milk and that resources set aside to set up anti-counterfeit measures eg customs monitoring by the likes of Interpol simply diverts Interpol from its core function. You can read Q&A session held by Christi van der Westhuizen and Wambi Michael on the IPS website here.

The problem this Afro Leo has with the comments of Musungu is that his apparent cynicism of what motivates global trade (which may be entirely correct) affects his judgement of whether anti-counterfeit legislation is per se good or bad. Yes, he was asked to explain the position against the backdrop of the certain controversial provisions which may affect access to cheap drugs but he does not reconcile his apparent distaste for anti-counterfeit legislation (as a totality) with the need to somehow also protect the fruits of the research of those his organisation represents. To be fair he was not asked to, but he would probably find that anti-counterfeit legislation, as a concept, would assist those researchers.

Paul, any thoughts?
Read More

Sunday, 13 September 2009

Darren Olivier

Counterfeit medicine clicks

The World Health Organization (WHO) has stepped up their efforts to combat the creation and distribution of counterfeit malaria pills in Africa. WHO estimates that upwards of 2,000 children a day are being killed as a result of taking these phony medications. (MediaGlobal)

As part of United States efforts to combat transnational crime and promote the protection of intellectual property rights (IPR) worldwide, the State Department has approved eleven projects totaling $3.9 million in Fiscal Year 2009 (FY09) anticrime funds. These funds will enable U.S. law enforcement agencies and diplomatic missions to collaborate in the delivery of criminal enforcement training and technical assistance programs on IPR protection to foreign law enforcement partners. Sub-Saharan Africa Regional is allocated $972,000 for IPR regional workshops for law enforcement officials in West Africa (including Nigeria) and nations belonging to the East African Community (EAC) and Southern Africa Customs Union (SACU), with particular emphasis on fighting the spread of counterfeit pharmaceuticals, including HIV-AIDS drugs. (US department of State)

Rwanda - experts from Health Action International (HAI) Africa, a civil society organization, in conjunction with Oxfam, have warned that, a growing push by countries to enact anti-counterfeit laws could undermine access to affordable medicines in Africa. (allAfrica)
Read More

Friday, 14 August 2009

Darren Olivier

Whose right? - HIV activists call for People's Property Rights

The concept of a People's Property Right apparently conceived by economist Joseph Stiglitz is the solution supported by Javed Jabbar, a former senator and minister from Pakistan, in a speech in Bali at the 9th International Conference on AIDS in Asia and the Pacific (ICAAP). He suggests setting up a fund to pay fees to scientists who come up with cures for key diseases - after which the [IP rights in and to] the drugs would go into the public domain instead of being ‘owned’ by pharmaceutical companies. Johanna Son reports further here and the leo highlights:

"These are medicines that make for life and death," argued Jabbar, also global vice president for the International Union for the Conservation of Nature. By applying the patent system to the drug product and the process, "we create inherently unjust monopolies and block knowledge transfer" that could save so many lives around the world.

It is time to rewrite the rules of intellectual property rights, a pillar of the world trade system, critics like Jabbar argue. "In the context of HIV and AIDS, we need a new concept of people’s property rights instead of intellectual property rights."


This Afro Leo believes that the concept of "people's property rights" already exists. For example, exclude recipes, algorithms, business methods, software etc from patent protection and what happens, they cannot be protected by patents and end up in the public domain ie they are no different to "people's property rights" and the people who create them are paid by way of a fee or charge. Assume for a moment though that the concept evolved from a Jabber/Stiglitz soundbite into a recognised form of property right, then consider what would would be right in circumstances where a HIV scientist employed by a pharma company came up with a cure for Aids using a plant extract that had been developed by a poor (in terms of money) indigenous community (protected by TK) with a high HIV mortality rate. Jabber would want that cure to be free for all (the People's Property Rights soundbite), the indigenous community (assuming it could be defined) would want recognition and wealth (through some right to the IP in the cure) to help its people, and the pharma company an incentive (in the form of an IP right) to keep on employing good HIV scientists. Whose right?
Read More